FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.
What happened
FDA inspected the facility from September 2 to 6, 2024, and found significant CGMP deviations for active pharmaceutical ingredients. FDA found the company's impurity test methods were not shown equivalent to USP methods, its impurity limits were looser than USP, and one U.S. shipment exceeded the USP single-impurity limit; it also found inadequate stability data and inadequate cleaning validation. FDA placed products offered for import into the United States from the firm on Import Alert 66-40 on January 24, 2025.
What FDA found
FDA found the company's impurity test methods were not shown equivalent to USP methods and its impurity limits were looser than USP, and one U.S. shipment exceeded the USP single-impurity limit.
FD&C Act section 501(a)(2)(B) and 501(b), 21 U.S.C. 351(a)(2)(B), 351(b)The quality unit lacked adequate stability data, including raw data, to support API retest dates.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Cleaning validation for shared API equipment was inadequate, relying on visual inspection without analytical residue data or procedures for other equipment.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The quality system was ineffective, with insufficient management oversight and quality unit authority.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective actions and prevention steps. It specifically requests USP-equivalent method commitments or studies, reserve-sample testing, a stability-program assessment, cleaning-validation improvements, and clarification about future U.S. manufacturing.
Who should pay attention
- drugmakers that buy APIs from this firm
- U.S. customers and distributors receiving its APIs
- quality teams auditing Chinese API suppliers
This is a summary. Read the original letter on fda.gov.